Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech ...
According to a joint report published today from the NHS Confederation and ABPI, collaborative work between the NHS and industry can offer a chance to improve patient care and reduce variations in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results